HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
INSIDE INDUSTRY
Mundipharma signs exclusive agreement with Helsinn Group for distribution of Anamorelin® across key markets in SEA

Mundipharma has entered a license agreement with Helsinn for the exclusive rights to develop, manufacture and commercialise Anamorelin®, a novel compound for the treatment of weight loss in cancer patients suffering from Non-Small Cell Lung Cancer (NSCLC) across the ten markets of Singapore, Indonesia, Malaysia, the Philippines, Brunei, Myanmar, Cambodia, Laos, Thailand and Vietnam.

Anamorelin® is a synthetic, orally active ghrelin receptor agonist that shows promise to treat cancer anorexia-cachexia in patients suffering from NSCLC. Attributed to about one-third of cancer deaths, cancer anorexia-cachexia syndrome (CACS) is a disorder that is mainly characterized by muscle atrophy and subsequent cancer induced weight loss (CIWL).

Studies have shown that there is a high correlation between CIWL and early deaths for cancer patients, with a significantly higher number of early deaths reported for patients who lost more than 5% of their body weight as compared to those who lost less than 5% of their body weight. It is estimated that over 50% of late-stage cancer patients suffer from cancer anorexia-cachexia and CIWL as a result. With no truly effective treatment available in the market today, products such as Anamorelin® will play a significant role in meeting the needs of this substantial number of patients.

"We are excited to further expand our partnership with Helsinn and supplement our portfolio of products for supportive care of patients with cancer," said Raman Singh, Regional Managing Director of Mundipharma Asia Pacific, Latin America, Middle East and Africa. "This partnership will help us in our mission to alleviate the burden of pain for cancer patients in the key markets where we operate."

Anamorelin® is currently undergoing two phase III studies, ROMANA 1 and ROMANA 2, which are running in parallel, to evaluate the efficacy of the drug in the treatment of CACS. Both of these trials are expected to complete by the end of 1H 2014.

"This partnership is another step in what we foresee as a long and fruitful association with Mundipharma. We are confident that Anamorelin® will present an important advancement in the management of cancer anorexia-cachexia," said Dr Riccardo Braglia, CEO, Helsinn Group.

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy